Evidenced-based approaches to support the development of endocrine-mediated Adverse Outcome Pathways: Challenges and Opportunities

Abstract

Copyright: © 2021 Audouze, Zgheib, Abass, Baig, Forner-Piquer, Holbech, Knapen, Leonards, Lupu, Palaniswamy, Rautio, Sapounidou and Martin. Adverse outcome pathways (AOP) have captured the attention of regulators and researchers alike as a systematic approach for organizing toxicological knowledge. AOPs can help identify Key Events (KE) that could be targeted for the development of New Approach Methods (NAM) and fit in Integrated Approaches to Testing and Assessment, as such they are an integral part of activities within the EURION cluster of projects developing new methods to identify endocrine disrupters. Although AOP development does not currently explicitly require the use of evidence-based methods (EBM), efforts are ongoing to recommend developers document the most important aspects of their process. This perspective article draws on lessons learnt from activities within the EURION cluster to review the circumstances in which EBMs approaches may be most usefully applied to endocrine-mediated (EM) AOP development and opportunities for further research and development of tools tailored to mechanistic evidence gathering and evaluation. We argue that; (1) systematic evidence mapping may support problem formulation in complementing canonical knowledge and identifying key event relationships (KER) for which systematic review (SR) is appropriate, (2) some selected machine learning tools (MLT) are identified as suitable to support the earlier stages of SR adapted to endocrine-mediated AOP development such as problem formulation or the design of search strategies, (3) their implementation for information retrieval ought to be validated and compared with manual methods, (4) whilst the feasibility and desirability of their application to the appraisal of evidence or the evaluation strength of the overall body of evidence is not yet demonstrated.European Union’s Horizon 2020 research and innovation programme under grant agreements No. 825712 (OBERON), No. 825759 (ENDpoiNTs), No. 825489 (GOLIATH), No. 825753 (ERGO), No. 825762 (EDCMET) and No. 825161 (ATHENA) all part of the EURION cluster